Finance Watch: Joe Jimenez Ventures Into Start-Up World Via Aditum
Also, Three New Biopharma IPOs Bring 2020 Total To 74 In US
Former Novartis CEO Jimenez co-founded Aditum with former NIBR president Mark Fishman; they raised $133m and are launching Tempero Bio. Also, Atea, Galecto and SQZ went public along with one more health care SPAC, Royalty Pharma upped its Vertex royalty revenues and Mirati’s FOPO raised $926.3m.
You may also be interested in...
The failed muscle-adding antibody could offer a superior profile in obesity by reducing body fat composition while increasing lean mass, the firm believes.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Having been under GSK's umbrella since 1985, SR One is striking out on its own, having closed the largest first-time VC fund this year.